The holy grail of gene therapy? As the precise link between individual genes and diseases is still largely unknown, developmental biology is emerging as a promising technology to identify the functional relationship between specific genes and disease processes. This powerful technology enables researchers to select and validate optimal therapeutic targets.
On March 26 and 27 in Boston, Mass., more than 25 of the leading developmental biology researchers and clinicians will describe the field's history and growth, present current research findings and discuss the potential and directions for new drug therapy based on developmental biology at a conference sponsored by Nature Biotechnology and Massachusetts General Hospital.
At "PharmacoGenesis: Postgenomic Drug Discovery Through Developmental Biology," Christiane Nusslein-Volhard, Ph.D., Nobel Laureate, will provide an overview of the industry in her keynote address. In addition, a roundtable discussion will include Rachel Leheny, Ph.D., senior biotechnology analyst at Hambrecht & Quist on "Building The Business Infrastructure." The conference will also feature discussions by top scientists and industry leaders including:
- Doros Platika, M.D., President, CEO, Ontogeny, Inc.
- George Scangos, Ph.D., President and CEO Exelixis Pharmaceuticals
- Patricia Kilian, Ph.D., Vice President of Metabolic Disease Research, Pharmacia & Upjohn
- George Morstyn, MB, BS, Ph.D., Vice President of Clinical Development and Chief Medical Officer, Amgen Inc.
- Mark Fishman, M.D., Chief, Cardiovascular Division, Director, Cardiovascular Research, Massachusetts General Hospital
- Gerald Rubin, Ph.D., Professor of Genetics, University of California, Berkeley
- Arnon Rosenthal, Ph.D., Scientist, Genentech, Inc.
- Doug Melton, Ph.D., Professor, Molecular and Cellular Biology, Harvard University
- Corey D. Goodman, Ph.D., Head of Neurobiology Division, University of California at Berkeley
When: March 26-27, 1998
Where: Boston Park Plaza Hotel, Boston, MA
Who: Sponsored by Nature Biotechnology and The Massachusetts General Hospital
RSVP: Bristol Conference Management Phone: 201-507-0899 Fax: 201-939-8515
Additional specialists will present findings and updates on the developmental biology field and its application to functional screening, the central nervous system, hematopoeisis, diabetes, bone metabolism and oncology.
For more information and a detailed schedule, please visit our website at: http://www.noonanrusso.com
To receive abstracts, or to arrange interviews, please call Renee Solano, Noonan/Russo Communications, 212-696-4455, x227 or renee@noonanrusso.com